9 completed, 1 active not recruiting, 1 not yet recruiting, 1 terminated. 7 Phase 2, 4 Phase 1, 1 Early Phase 1, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 4, Active not recruiting 1, Not yet recruiting 1, Withdrawn 1 |
| Phase 1 | 4 | Completed 4 |
| Early Phase 1 | 1 | Completed 1 |
| Not applicable | 1 | Unknown 1 |
| Phase 3 | 1 | Completed 1 |
Follow Montanide ISA 51 VG: new trials by email Literature Review of Montanide ISA 51 VG trials Research Report on Montanide ISA 51 VG
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the SurVaxM Vaccine for Lung Cancer Prevention Biospecimen Collection, Montanide ISA 51 VG, Questionnaire Administration - Lung Carcinoma | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 80 | 2026-10-01 | 2026-08-26 |
| KLH Challenge to Explore the Human Immune Response Keyhole-Limpet Hemocyanin, Saline, Montanide ISA 51 VG - Immune Response | Not applicable | Unknown | University of Oxford | 39 | 2023-03-01 | 2023-05-25 |
| The P10s-PADRE Basket Trial: Vaccination of Metastatic Cancer Patients P10s-PADRE - Neoplasms by Site, Metastatic Cancer | Phase 2 | Withdrawn | University of Arkansas | 2021-03-01 | 2024-09-03 | |
| SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Laboratory Biomarker Analysis, Montanide ISA 51 VG, Sargramostim - Glioblastoma, Gliosarcoma | Phase 2 | Active not recruiting | Roswell Park Cancer Institute | 66 | 2015-05-04 | 2026-10-22 |
| Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery Montanide ISA 51 VG, MART-1 antigen, laboratory biomarker analysis - Recurrent Melanoma, Stage IIA Melanoma | Early Phase 1 | Completed | Mayo Clinic | 30 | 2012-10-01 | 2018-10-09 |
| Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission basiliximab, WT1 126-134 peptide vaccine, Montanide ISA 51 VG - Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Phase 1 | Completed | University of Chicago | 7 | 2011-12-05 | 2018-03-09 |
| Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558 MART-1, NY-ESO-1, gp100:209-217(210M) - Melanoma (Skin) | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 127 | 2010-08-04 | 2023-01-18 |
| Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma MART-1: 26-35(27L) Peptide, Montanide ISA 51 VG, gp100:154-162 Peptide - Melanoma, Skin Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 4 | 2008-12-01 | 2015-10-28 |
| EMD 640 744 in Montanide ISA 51 VG Administered in Subjects With Advanced Solid Tumors EMD 640744, Montanide ISA 51 VG - Advanced Solid Tumors | Phase 1 | Completed | Merck KGaA, Darmstadt, Germany | 104 | 2008-04-01 | 2014-02-20 |
| Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma tyrosinase peptide, gp100 antigen, MART-1 antigen - Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 40 | 2004-06-01 | 2015-04-15 |
| Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma gp100 antigen, tyrosinase peptide, recombinant MAGE-3.1 antigen - Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size | Phase 2 | Completed | University of Southern California | 42 | 2004-05-01 | 2014-05-22 |
| Vaccination With Tetanus and KLH to Assess Immune Responses. Intracel KLH Vaccine, Biosyn KLH, Montanide ISA51 - Cancer | Terminated | Masonic Cancer Center, University of Minnesota | 112 | 2002-07-01 | 2017-11-29 | |
| Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma Aldesleukin, gp100 Antigen, Montanide ISA 51 VG - Recurrent Melanoma, Stage IIIA Skin Melanoma | Phase 3 | Completed | National Cancer Institute (NCI) | 185 | 1999-12-01 | 2017-11-20 |
| Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome PR1 leukemia peptide vaccine, Montanide ISA 51 VG, sargramostim - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 69 | 1999-12-01 | 2013-01-07 |
Melanoma (6) · Uveal Melanoma (2) · Anemia, Refractory, with Excess of Blasts (1) · Congenital Abnormalities (1) · Glioblastoma (1) · Gliosarcoma (1) · Leukemia, Myeloid, Accelerated Phase (1) · Leukemia, Myeloid, Chronic-Phase (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Neoplasms by Site (1) · Skin Neoplasms (1)
National Cancer Institute (NCI) (5) · H. Lee Moffitt Cancer Center and Research Institute (1) · Masonic Cancer Center, University of Minnesota (1) · Mayo Clinic (1) · Merck KGaA, Darmstadt, Germany (1) · Roswell Park Cancer Institute (1) · University of Arkansas (1) · University of Chicago (1) · University of Oxford (1) · University of Southern California (1)
United States (11) · United Kingdom (1)
Jeffrey Weber (2) · Douglas Schwartzentruber (1) · Hongtao Liu (1) · Issam Makhoul, MD (1) · James Fullerton, MBBS (1) · Jeffrey Miller, MD (1) · Jens-Peter Marschner, MD (1) · Muzaffar Qazilbash (1) · Nikhil I. Khushalani, M.D. (1) · Robert Fenstermaker (1) · Saikrishna S Yendamuri (1) · Steven Rosenberg, M.D. (1) · Svetomir Markovic, M.D., Ph.D. (1)
PMID 21631324, PMID 23861247, PMID 24145345, PMID 24487961, PMID 29344432, PMID 36521103
P30CA060553 (1), UG1CA242643 (1)